Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bast

Showing results (411-420 of 560) with videos related to

Pageof 56
Sort By:
American Journal of Obstetrics and Gynecology|May 18, 2010
Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic massRichard G Moore, Moune Jabre-Raughley, Amy K Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Project Zero Delay: a process for accelerating the activation of cancer clinical trialsRazelle Kurzrock, Susan Pilat, Marcel Bartolazzi, et al.
Molecular Oncology|March 12, 2022
SIK2 promotes ovarian cancer cell motility and metastasis by phosphorylating MYLKXiu Shi, Xuejiao Yu, Juan Wang, et al.
Cancer|April 15, 2011
Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagyMin-Yu Chen, Warren S-L Liao, Zhen Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2004
Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancerGordon J S Rustin, Robert C Bast, Gary J Kelloff, et al.
Medrxiv : the Preprint Server for Health Sciences|July 15, 2025
GlycoKnow Ovarian: a Glycoprotein-based, Serum Diagnostic to Distinguish Ovarian Cancers from Benign Pelvic MassesDaniel Serie, Kaitlynn Moser, Maurice Wong, et al.
AIDS (London, England)|February 15, 2021
Risk of adverse coronavirus disease 2019 outcomes for people living with HIVMaya M Mellor, Anne C Bast, Nicholas R Jones, et al.
Gynecologic Oncology|December 7, 2007
The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic massRichard G Moore, Amy K Brown, M Craig Miller, et al.
Journal of Medicinal Chemistry|April 14, 2011
Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3Pijus K Mandal, Fengqin Gao, Zhen Lu, et al.
Cancer|August 27, 1999
Communication skills training in oncology. Description and preliminary outcomes of workshops on breaking bad news and managing patient reactions to illnessW F Baile, A P Kudelka, E A Beale, et al.
Pageof 56

Showing results (411-420 of 560) with videos related to

Sort By:
Pageof 56
American Journal of Obstetrics and Gynecology|May 18, 2010
Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic massRichard G Moore, Moune Jabre-Raughley, Amy K Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Project Zero Delay: a process for accelerating the activation of cancer clinical trialsRazelle Kurzrock, Susan Pilat, Marcel Bartolazzi, et al.
Molecular Oncology|March 12, 2022
SIK2 promotes ovarian cancer cell motility and metastasis by phosphorylating MYLKXiu Shi, Xuejiao Yu, Juan Wang, et al.
Cancer|April 15, 2011
Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagyMin-Yu Chen, Warren S-L Liao, Zhen Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2004
Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancerGordon J S Rustin, Robert C Bast, Gary J Kelloff, et al.
Medrxiv : the Preprint Server for Health Sciences|July 15, 2025
GlycoKnow Ovarian: a Glycoprotein-based, Serum Diagnostic to Distinguish Ovarian Cancers from Benign Pelvic MassesDaniel Serie, Kaitlynn Moser, Maurice Wong, et al.
AIDS (London, England)|February 15, 2021
Risk of adverse coronavirus disease 2019 outcomes for people living with HIVMaya M Mellor, Anne C Bast, Nicholas R Jones, et al.
Gynecologic Oncology|December 7, 2007
The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic massRichard G Moore, Amy K Brown, M Craig Miller, et al.
Journal of Medicinal Chemistry|April 14, 2011
Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3Pijus K Mandal, Fengqin Gao, Zhen Lu, et al.
Cancer|August 27, 1999
Communication skills training in oncology. Description and preliminary outcomes of workshops on breaking bad news and managing patient reactions to illnessW F Baile, A P Kudelka, E A Beale, et al.
Pageof 56